BioInformant - Stem Cell Industry News
@bioinformant.bsky.social
As the first and only market research firm to specialize in the stem cell industry, BioInformant.com is read by nearly 1 million readers per year. BioInformant has been cited by WSJ, Xconomy, and Vogue, as well as featured in Tony Robbin's book Life Force.
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - bioinformant.com/ipsc-derived...
@aspenneuroscience.bsky.social @greenstonebio.bsky.social @novonordisk.bsky.social @reprocell.bsky.social @riken-brc-en.bsky.social
@aspenneuroscience.bsky.social @greenstonebio.bsky.social @novonordisk.bsky.social @reprocell.bsky.social @riken-brc-en.bsky.social
The Pipeline for of iPSC-Derived Cell Therapeutics in 2026
While iPSCs are commonly used in drug discovery, we remain in the early stages of using iPSC-derived cell therapeutics in humans.
bioinformant.com
November 10, 2025 at 4:39 PM
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - bioinformant.com/ipsc-derived...
@aspenneuroscience.bsky.social @greenstonebio.bsky.social @novonordisk.bsky.social @reprocell.bsky.social @riken-brc-en.bsky.social
@aspenneuroscience.bsky.social @greenstonebio.bsky.social @novonordisk.bsky.social @reprocell.bsky.social @riken-brc-en.bsky.social
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD | BioInformant
In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogen...
bioinformant.com
November 9, 2025 at 5:46 AM
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 - bioinformant.com/roosterbio-a...
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 | BioInformant
FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Se...
bioinformant.com
November 6, 2025 at 3:48 PM
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 - bioinformant.com/roosterbio-a...
BBG Advanced Therapies collects first cell donation on one-of-a-kind bus - bioinformant.com/bbg-advanced...
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
BBG Advanced Therapies collects first cell donation on one-of-a-kind bus | BioInformant
New vehicle to help enable lifesaving new advanced therapies The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global ...
bioinformant.com
October 29, 2025 at 7:14 PM
BBG Advanced Therapies collects first cell donation on one-of-a-kind bus - bioinformant.com/bbg-advanced...
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - bioinformant.com/big-pharma-c...
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering | BioInformant
Across 2025, a striking trend has emerged in biotechnology. Major pharmaceutical companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body ...
bioinformant.com
October 27, 2025 at 2:56 AM
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - bioinformant.com/big-pharma-c...
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research - bioinformant.com/cirms-ipsc-r...
@cirmnews.bsky.social
@cirmnews.bsky.social
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research | BioInformant
Sadly, in July 2025, the California Institute for Regenerative Medicine (CIRM) officially closed its iPSC Repository, marking the end of one of the world’s most comprehensive publicly funded collectio...
bioinformant.com
October 24, 2025 at 6:56 AM
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research - bioinformant.com/cirms-ipsc-r...
@cirmnews.bsky.social
@cirmnews.bsky.social
NFL legend Bernie Kosar launches the X Pro Athlete Cognitive Longevity Program with the Crowley Center and Regenerelle® to push the limits of brain performance
bioinformant.com/bernie-kosar...
bioinformant.com/bernie-kosar...
Legendary NFL Quarterback Bernie Kosar Launches X Pro. Athlete Cognitive Longevity Wellness Program to Push the Limits of Brain Performance with Crowley Center for Regenerative Biotherapeutics in coll...
Backed by a $10M Age Zero™ Regenerelle® in-kind contribution by the Crowley Family, Team Bernie™ brings together NFL veterans and longevity innovators to explore next-generation cognitive optimizatio...
bioinformant.com
October 23, 2025 at 8:22 PM
NFL legend Bernie Kosar launches the X Pro Athlete Cognitive Longevity Program with the Crowley Center and Regenerelle® to push the limits of brain performance
bioinformant.com/bernie-kosar...
bioinformant.com/bernie-kosar...
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease - bioinformant.com/qihan-biotec...
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease | BioInformant
A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer ...
bioinformant.com
October 19, 2025 at 2:44 AM
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease - bioinformant.com/qihan-biotec...
Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2025 - bioinformant.com/ipsc-industr...
@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social
@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social
Induced Pluripotent Stem Cell (iPSC) Industry Trends for 2025
Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using non-controversial adult cells. They are derived from somatic cells through reprog...
bioinformant.com
October 18, 2025 at 1:02 PM
Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2025 - bioinformant.com/ipsc-industr...
@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social
@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential - bioinformant.com/novo-withdra...
@novonordisk.bsky.social
@novonordisk.bsky.social
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential | BioInformant
Sadly, Novo Nordisk has ended its $598 million collaboration with Tokyo-based biotech Heartseed, marking a major shift in its approach to regenerative medicine and iPSCs, specifically. The partnershi...
bioinformant.com
October 14, 2025 at 8:00 PM
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential - bioinformant.com/novo-withdra...
@novonordisk.bsky.social
@novonordisk.bsky.social
TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee - bioinformant.com/trihaz-solut...
TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee | BioInformant
Nashville, TN – July 16, 2025 – TriHaz Solutions, a trusted provider of regulated medical waste management, is proud to announce the opening of a new operational facility in Nashville, Tennesee. This ...
bioinformant.com
October 12, 2025 at 5:30 PM
TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee - bioinformant.com/trihaz-solut...
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells - bioinformant.com/ubrigene-ips...
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells | BioInformant
GERMANTOWN, MD, September 17, 2025 – uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powere...
bioinformant.com
October 10, 2025 at 6:57 AM
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells - bioinformant.com/ubrigene-ips...
TEDCO Announces Panel to Discuss Road to Clinical Trials at 2025 Entrepreneur Expo - bioinformant.com/tedco-panel-...
TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.
TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.
TEDCO Announces Panel to Discuss the Road to Clinical Trials at 2025 Entrepreneur Expo | BioInformant
COLUMBIA, Md., October 9, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo at ...
bioinformant.com
October 10, 2025 at 12:38 AM
TEDCO Announces Panel to Discuss Road to Clinical Trials at 2025 Entrepreneur Expo - bioinformant.com/tedco-panel-...
TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.
TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study - bioinformant.com/xintelas-xst...
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study | BioInformant
The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pa...
bioinformant.com
October 9, 2025 at 6:01 PM
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study - bioinformant.com/xintelas-xst...
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF - bioinformant.com/kexing-bioph...
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF | BioInformant
SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (...
bioinformant.com
October 9, 2025 at 1:18 AM
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF - bioinformant.com/kexing-bioph...
Maryland Governor Wes Moore to Speak at TEDCO’s 2025 Entrepreneur Expo - bioinformant.com/maryland-gov...
TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo on Oct 21, 2025.
TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo on Oct 21, 2025.
Maryland Governor Wes Moore to Speak at TEDCO's 2025 Entrepreneur Expo | BioInformant
Join us in College Park on October 21 during the lunch keynote session COLUMBIA, Md., Sept. 29, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland ...
bioinformant.com
October 8, 2025 at 4:08 PM
Maryland Governor Wes Moore to Speak at TEDCO’s 2025 Entrepreneur Expo - bioinformant.com/maryland-gov...
TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo on Oct 21, 2025.
TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo on Oct 21, 2025.
Qkine launches cell therapy grade recombinant proteins to support next-generation therapies - bioinformant.com/qkine/
@qkine.bsky.social
@qkine.bsky.social
Qkine launches cell therapy grade recombinant proteins to support next-generation therapies | BioInformant
1st October 2025, Cambridge, UK – Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell The...
bioinformant.com
October 8, 2025 at 11:19 AM
Qkine launches cell therapy grade recombinant proteins to support next-generation therapies - bioinformant.com/qkine/
@qkine.bsky.social
@qkine.bsky.social
Heartbeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies - bioinformant.com/heartbeat-bi...
HeartBeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies | BioInformant
HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research col...
bioinformant.com
October 7, 2025 at 5:43 AM
Heartbeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies - bioinformant.com/heartbeat-bi...
Clinical #StemCell Services: REPROCELL's experts in cell therapy manufacturing will take you through all the stages of your regenerative medicine project
www.reprocell.com/clinical-ste...
www.reprocell.com/clinical-ste...
October 6, 2025 at 5:00 PM
Clinical #StemCell Services: REPROCELL's experts in cell therapy manufacturing will take you through all the stages of your regenerative medicine project
www.reprocell.com/clinical-ste...
www.reprocell.com/clinical-ste...
CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank - bioinformant.com/cytomed-ther...
@cytomedtech.bsky.social
@cytomedtech.bsky.social
CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank | BioInformant
CytoMed Therapeutics Seeks to Advance Cord Blood-Derived Therapies For Auto-immune Diseases and Cancers Long-term intention is to spin off LongevityBank as standalone biotech, offering immune cell ban...
bioinformant.com
October 6, 2025 at 3:12 AM
CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank - bioinformant.com/cytomed-ther...
@cytomedtech.bsky.social
@cytomedtech.bsky.social
Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip - bioinformant.com/mytos-announ...
Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip | BioInformant
Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials Mytos’ iDEM platform replaces traditional iPSC manufacturing with a ...
bioinformant.com
October 4, 2025 at 1:12 AM
Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip - bioinformant.com/mytos-announ...
European Commission Grants First Approval for Expanded Cord Blood Stem Cell Therapy (Zemcelpro®) - bioinformant.com/european-com...
European Commission Grants First Approval for Expanded Cord Blood Stem Cell Therapy (Zemcelpro®) | BioInformant
September 10, 2025 — In a landmark move for regenerative medicine, the European Commission has conditionally authorized Zemcelpro®, the first treatment in Europe to use expanded umbilical cord blood s...
bioinformant.com
October 1, 2025 at 2:11 PM
European Commission Grants First Approval for Expanded Cord Blood Stem Cell Therapy (Zemcelpro®) - bioinformant.com/european-com...
Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production - bioinformant.com/takara-bio-e...
Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production | BioInformant
September 24, 2025 – Takara Bio Europe announces the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human ...
bioinformant.com
September 27, 2025 at 9:19 AM
Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production - bioinformant.com/takara-bio-e...
Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research - bioinformant.com/ncardia-ipsc...
Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research | BioInformant
LEIDEN, Netherlands — Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment, today announced the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially availa...
bioinformant.com
September 26, 2025 at 7:52 PM
Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research - bioinformant.com/ncardia-ipsc...
Congress Moves to Reauthorize Funding for National Cord Blood and Bone Marrow Transplant Programs - bioinformant.com/fundering-co...
Congress Moves to Reauthorize Funding for National Cord Blood and Bone Marrow Transplant Programs | BioInformant
Legislation would authorize $280 million over 5 years to support National Cord Blood and Bone Marrow Transplant Programs. A bipartisan group of lawmakers in the U.S. House has introduced new legislati...
bioinformant.com
September 26, 2025 at 4:57 AM
Congress Moves to Reauthorize Funding for National Cord Blood and Bone Marrow Transplant Programs - bioinformant.com/fundering-co...